New contrast mammogram spots hidden breast tumors

NCT ID NCT05036083

Completed Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether contrast-enhanced mammography (CEM) can find more breast cancers than standard mammography in women already diagnosed with breast cancer. 89 women received CEM, which uses an iodine dye to highlight suspicious areas. The goal was to see if CEM detects additional tumors and reduces the need for biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodinated contrast agent
What this could lead to: If successful, CEM could become a standard tool for staging breast cancer, helping doctors find additional tumors and avoid unnecessary biopsies.
What could go wrong: This is a small, completed study (89 participants) at a single center. Results may not apply to all patients, and CEM involves radiation and contrast dye risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast carcinoma in situ breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA INVASIVE BREAST CARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.